CION Ameerpet
You want one answer: can the treatment be planned so that a pregnancy is still possible for you? Eligibility is decided by what the tumour is, how far it has travelled, and how completely it can be staged — not by how young you are or how much you want a child. This page sets out the criteria plainly, in the order a specialist works through them.
Most women searching fertility sparing eligibility ovarian cancer are looking for a rule they can apply to themselves at midnight. There is one, and it is shorter than you would expect. Eligibility turns on four things: what the tumour is under the microscope, how far it has spread, what the opposite ovary and the uterus look like, and whether the operation included complete surgical staging. Your age is not on that list. Neither is how badly you want a baby.
That matters, because the criteria are not a judgement about you. A 24-year-old with a high-grade tumour that has spread is not eligible, and a 38-year-old with a borderline tumour confined to one ovary usually is. The question who can have fertility sparing ovarian surgery is answered by pathology and staging, in that order.
The second thing to understand is that an early answer is provisional. Ovarian cancer is staged in theatre, not on a scan, and the tumour type on a frozen section during the operation is not always the type the final report gives a week later. So a specialist will often say this looks like a case where we can keep the other ovary before surgery, and confirm or withdraw it afterwards. For what the operation itself involves, see fertility-sparing surgery; for the wider set of options, including what to do when surgery cannot be spared, start with ovarian cancer and fertility.
Borderline tumours, malignant germ cell tumours and sex cord-stromal tumours are the groups where fertility-sparing management is most often reasonable. High-grade serous carcinoma is not.
Disease confined to one ovary, an intact capsule and negative washings support it. Anything found outside the ovary in an epithelial cancer removes it from the table.
A frozen section in theatre guides the surgeon on the day. The final histopathology, several days later, is what settles eligibility for good.
Eligibility cannot be settled by a scan, because ovarian cancer is staged surgically, not radiologically — the FIGO stage comes from what is washed, inspected and biopsied in theatre. In the classic Gynecologic Oncology Group staging-laparotomy study, women referred with apparently early ovarian cancer who then underwent comprehensive surgical restaging were found to have more advanced disease in roughly a third of cases. Nothing about the tumour had changed; only the thoroughness of the look. That single finding is why complete staging is written into the eligibility criteria, and why a woman whose ovarian tumour was removed without staging is usually advised to have the staging completed before fertility-sparing management is called safe. Source: Young RC et al., JAMA (1983), staging laparotomy in early ovarian cancer; FIGO ovarian cancer staging; NCCN Ovarian Cancer guidelines.
This is the checklist a gynaecologic oncologist works through. No single line decides the case on its own, and the rows are not equally weighted — tumour type and spread carry far more than the rest.
| What is being judged | Points towards fertility-sparing | Points away from it |
|---|---|---|
| Tumour type | Borderline tumour, malignant germ cell tumour, sex cord-stromal tumour, or low-grade epithelial cancer. | High-grade serous carcinoma, and most clear cell and undifferentiated tumours. |
| Grade | Grade 1 or low grade, where the cells still resemble the tissue they came from. | Grade 3 or high grade, where behaviour is harder to predict and recurrence is commoner. |
| Spread beyond the ovary | Disease confined to one ovary, capsule intact, peritoneal washings negative — stage IA. | Implants, positive washings or disease on the peritoneum, omentum or nodes. Malignant germ cell tumours are the recognised exception: fertility-sparing surgery is still considered beyond stage I, because they respond well to chemotherapy. |
| The opposite ovary | Normal on imaging and normal to the surgeon's eye and touch during the operation. | Visibly abnormal, or involved by tumour. Keeping an ovary that is already diseased protects nothing. |
| The uterus | Normal, with no second cancer of the uterine lining present. | Tumour involving the uterus, or a coexisting endometrial cancer, which several ovarian subtypes travel with. |
| Surgical staging | Comprehensive staging done at the first operation, or completed at a second. | No staging performed, or the mass removed piecemeal so that spread cannot be excluded. This is a not yet, not always a no. |
| Inherited risk | No pathogenic BRCA1 or BRCA2 variant, and no strong family pattern. | A BRCA1 or BRCA2 variant. It rarely cancels the operation outright, but it shortens the window: removing the remaining ovary and tubes becomes part of the long-term plan. |
| Follow-up | Able to attend structured surveillance of the retained ovary for years, not months. | No realistic way to attend follow-up. Fertility-sparing management is a commitment, not a single decision. |
*Read this as a weighing exercise, not a scorecard. Two women with the same FIGO stage can get different answers because the subtype, the grade and the completeness of staging differ.
Most of the distress in this area comes from being told one thing before surgery and something different afterwards. These are the six reasons that happens. None of them is anyone's fault, and none of them means a family is out of reach — it means the route to one changes.
A frozen section in theatre gives the surgeon a working answer within minutes, but it is a rapid look at a small sample. If the full report several days later reads high-grade serous carcinoma, the plan moves to standard surgery.
Washings, peritoneal biopsies or the omentum showing tumour cells means the disease was never confined to the ovary that was removed. In epithelial cancer this ends fertility-sparing management.
If the remaining ovary looks or feels wrong during the operation, the surgeon has to act on what is in front of them. This is exactly why the conversation belongs in the consent discussion.
Common when a cyst is removed at a general hospital and turns out to be cancer. It is a pause rather than a refusal: the staging is completed first, and then eligibility is decided on real information.
An inherited BRCA1 or BRCA2 result does not usually cancel the operation you have already had. It does change what happens later: removing the remaining ovary and both tubes becomes part of the plan, and the window for conceiving becomes a defined one rather than an open one. Genetic counselling and testing are delivered in-house at CION.
Endometrioid ovarian tumours in particular can coexist with a cancer of the uterine lining. If the uterus is affected, carrying a pregnancy is no longer possible, and the conversation turns to what else can be preserved. Start with ovarian cancer and fertility.
If your plan has changed for one of these reasons, ask for the final histopathology report and a tumour board opinion before accepting that nothing further is possible. Second opinions are free at CION, and this is precisely the kind of decision that deserves more than one pair of eyes.
Bring the scan, the reports and the operative note if there is one. A 45-minute consultation and a tumour board review will tell you whether fertility-sparing management is genuinely on the table for you, and what has to happen next if it is.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If the answer is no, you will be told plainly and shown what else can be done to protect your chance of a family.
A great many women reach this question the wrong way round: an ovarian cyst was removed, the report came back as cancer, and nobody discussed fertility before theatre. Eligibility can still be worked out, but it has to be reconstructed from documents. This is the order to do it in.
Not the discharge summary, not a verbal account — the signed report. It should name the subtype, the grade, whether the capsule was intact or ruptured, and what the washings showed. Those four lines carry more weight in the eligibility decision than anything else in your file.
This tells you what was actually removed and whether staging was performed: peritoneal washings taken, the peritoneum inspected and biopsied, the omentum removed, lymph nodes assessed. If the note describes only a cystectomy or the removal of one ovary, staging was not done, and that is the single most fixable gap.
A post-operative CT of the chest, abdomen and pelvis looks for disease outside the pelvis, and the tumour markers appropriate to your age and subtype give a baseline to follow. In a young woman that means the germ cell and stromal markers alongside CA-125, not CA-125 alone.
One clinician reading one report is how eligibility gets misjudged in both directions — women told a family is impossible when it is not, and women reassured when the pathology does not support it. At CION every case that raises a question goes to a multidisciplinary board. You can ask a CION specialist for that review directly.
Where staging was never done, the choice is between a second, staging operation and close surveillance. It is a real decision with arguments on both sides, and it depends on subtype, grade and how the first operation was performed. Staging surgery and fertility-sparing surgery are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there — we say so upfront.
If chemotherapy is indicated, the conversation about protecting ovarian function belongs before the first cycle, not after it. Chemotherapy and maintenance treatment are delivered in-house at CION across 35+ centres, so the fertility discussion happens with the team that will actually be treating you.
Eligibility for fertility-sparing treatment is a documents-and-pathology question, and it takes time to answer properly. It cannot be settled in a five-minute consultation, and it should not be settled by whoever is available on the day. Your first consultation at CION is free and runs to about 45 minutes — long enough to read the histopathology report line by line, look at the operative note, and tell you which of the criteria you actually meet.
Every case that raises a question goes to a tumour board rather than resting on one opinion. Where an inherited cause is in question, genetic counselling and BRCA and HRD testing are done in-house, because a BRCA result changes not only your treatment but the timetable you are planning a family against.
Two things we would rather you knew now than discovered later. Fertility-sparing surgery and comprehensive surgical staging are coordinated with specialist gynaecologic-oncology surgeons at partner centres, and may be billed there. What CION delivers itself is medical oncology — chemotherapy and maintenance treatment across 35+ centres in Telangana and Andhra Pradesh — along with genetic counselling, nutrition support and long-term follow-up of the ovary you keep.
Free, unhurried, and spent on your actual reports rather than a general talk about ovarian cancer. Bring the histopathology, the operative note and the scans.
Medical oncology, imaging and pathology together. Eligibility decisions of this weight should not be one clinician's call.
Counselling first, then BRCA and HRD testing where it is warranted. The result shapes how long the window for conceiving realistically stays open.
Staging and fertility-sparing surgery are performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there, with CION coordinating the pathway.
Broadly, a woman whose tumour is one of the lower-risk types, whose disease is confined to one ovary, whose other ovary and uterus are healthy, and whose operation included comprehensive surgical staging. The tumour types where it is most often reasonable are borderline tumours, malignant germ cell tumours, sex cord-stromal tumours and low-grade stage IA epithelial cancers. High-grade serous carcinoma is not in that group. Age is not a criterion, and neither is how many children you already have. What matters is what the pathologist reports and what the surgeon found and documented. Because ovarian cancer is staged in theatre rather than on a scan, an answer given before surgery is always provisional until the final report agrees with it.
Not automatically, though it is the single most favourable thing on the list. Stage IA means the tumour was confined to one ovary with an intact capsule and negative washings, and it is the stage at which fertility-sparing management is most often offered. But the subtype and grade sit alongside it. Stage IA high-grade serous carcinoma is treated differently from stage IA grade 1 endometrioid cancer, because the two behave differently over time. The other question is how the stage was arrived at: a stage assigned without comprehensive staging is an assumption, not a finding. If washings, peritoneal biopsies, the omentum and lymph nodes were not assessed, the staging usually needs completing before anyone can call you eligible with confidence.
Only provisionally, and any specialist who tells you otherwise is overpromising. Before surgery a team has imaging, tumour markers, your age and the appearance of the mass. That is often enough to say fertility-sparing management looks likely or looks unlikely, and it is enough to plan the operation around your wishes. What it cannot do is confirm the subtype or the spread. A frozen section during the operation gives the surgeon a rapid working answer, but it is a small sample examined quickly and it is sometimes revised. The final histopathology, usually several days later, together with the staging biopsies, is what settles the question. Record your fertility intention in the notes before consent is signed, so the surgeon knows what you want if a decision has to be made mid-operation.
Possibly, and this situation is far more common than people realise. A cyst is removed at a general hospital, the histopathology comes back as a borderline or malignant tumour, and nobody took washings or looked at the omentum. That is a gap in information, not a verdict. The usual next step is a review of the operative note and the pathology, a CT scan, and a decision about whether to complete the staging with a second operation or to follow you closely instead. Which route is right depends on the subtype, the grade and whether the tumour was removed intact. Ask for a tumour board opinion before agreeing to anything more radical, because completing staging can confirm eligibility rather than remove it.
No, not as a medical criterion. Nothing about being 22 or 39 changes what the tumour is or how far it has spread, and eligibility is decided on those two things. Age enters the conversation in a different place: it shapes how long you realistically have to conceive with one ovary, and how urgent the decision about the remaining ovary becomes once you have finished. A woman in her late thirties may be entirely eligible on pathology and still need to move quickly, while a woman of 25 has more room to plan. Number of existing children is a personal consideration, not a clinical filter, and it should not be used to talk you out of asking the question.
The first consultation is free and runs to about 45 minutes, which is enough time to read your histopathology report and operative note properly rather than skim them. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing, nutrition support and long-term follow-up. Fertility-sparing surgery and comprehensive surgical staging are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.